Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jessica Frankum

Showing results (1-10 of 23) with videos related to

Pageof 3
Sort By:
EMBO Molecular Medicine|August 31, 2012
Synthetic lethality of PARP and NAMPT inhibition in triple-negative breast cancer cellsIlirjana Bajrami, Asha Kigozi, Antoinette Van Weverwijk, et al.
Oncotarget|April 18, 2015
Complementary genetic screens identify the E3 ubiquitin ligase CBLC, as a modifier of PARP inhibitor sensitivityJessica Frankum, Pavel Moudry, Rachel Brough, et al.
BMC Genomics|November 16, 2012
Molecular characterisation of cell line models for triple-negative breast cancersAnita Grigoriadis, Alan Mackay, Elodie Noel, et al.
The Journal of Pathology|July 8, 2011
Functional characterization of EMSY gene amplification in human cancersPaul M Wilkerson, Konstantin J Dedes, Daniel Wetterskog, et al.
Stem Cells (Dayton, Ohio)|June 8, 2012
Targeting p90 ribosomal S6 kinase eliminates tumor-initiating cells by inactivating Y-box binding protein-1 in triple-negative breast cancersAnna L Stratford, Kristen Reipas, Kaiji Hu, et al.
Oncogene|June 29, 2022
Functional screening reveals HORMAD1-driven gene dependencies associated with translesion synthesis and replication stress toleranceDalia Tarantino, Callum Walker, Daniel Weekes, et al.
Genome Biology|October 25, 2011
High-throughput RNA interference screening using pooled shRNA libraries and next generation sequencingDavid Sims, Ana M Mendes-Pereira, Jessica Frankum, et al.
Oncogene|July 26, 2023
A HUWE1 defect causes PARP inhibitor resistance by modulating the BRCA1-∆11q splice variantStephen J Pettitt, Nan Shao, Diana Zatreanu, et al.
Molecular Cancer Therapeutics|June 17, 2017
Modeling Therapy Resistance in <i>BRCA1/2</i>-Mutant CancersAmy Dréan, Chris T Williamson, Rachel Brough, et al.
Scientific Data|March 2, 2017
Genome-wide barcoded transposon screen for cancer drug sensitivity in haploid mouse embryonic stem cellsStephen J Pettitt, Dragomir B Krastev, Helen N Pemberton, et al.
Pageof 3

Showing results (1-10 of 23) with videos related to

Sort By:
Pageof 3
EMBO Molecular Medicine|August 31, 2012
Synthetic lethality of PARP and NAMPT inhibition in triple-negative breast cancer cellsIlirjana Bajrami, Asha Kigozi, Antoinette Van Weverwijk, et al.
Oncotarget|April 18, 2015
Complementary genetic screens identify the E3 ubiquitin ligase CBLC, as a modifier of PARP inhibitor sensitivityJessica Frankum, Pavel Moudry, Rachel Brough, et al.
BMC Genomics|November 16, 2012
Molecular characterisation of cell line models for triple-negative breast cancersAnita Grigoriadis, Alan Mackay, Elodie Noel, et al.
The Journal of Pathology|July 8, 2011
Functional characterization of EMSY gene amplification in human cancersPaul M Wilkerson, Konstantin J Dedes, Daniel Wetterskog, et al.
Stem Cells (Dayton, Ohio)|June 8, 2012
Targeting p90 ribosomal S6 kinase eliminates tumor-initiating cells by inactivating Y-box binding protein-1 in triple-negative breast cancersAnna L Stratford, Kristen Reipas, Kaiji Hu, et al.
Oncogene|June 29, 2022
Functional screening reveals HORMAD1-driven gene dependencies associated with translesion synthesis and replication stress toleranceDalia Tarantino, Callum Walker, Daniel Weekes, et al.
Genome Biology|October 25, 2011
High-throughput RNA interference screening using pooled shRNA libraries and next generation sequencingDavid Sims, Ana M Mendes-Pereira, Jessica Frankum, et al.
Oncogene|July 26, 2023
A HUWE1 defect causes PARP inhibitor resistance by modulating the BRCA1-∆11q splice variantStephen J Pettitt, Nan Shao, Diana Zatreanu, et al.
Molecular Cancer Therapeutics|June 17, 2017
Modeling Therapy Resistance in <i>BRCA1/2</i>-Mutant CancersAmy Dréan, Chris T Williamson, Rachel Brough, et al.
Scientific Data|March 2, 2017
Genome-wide barcoded transposon screen for cancer drug sensitivity in haploid mouse embryonic stem cellsStephen J Pettitt, Dragomir B Krastev, Helen N Pemberton, et al.
Pageof 3